ProQR Therapeutics N.V. (NASDAQ:PRQR) Short Interest Update

ProQR Therapeutics N.V. (NASDAQ:PRQR) was the recipient of a large increase in short interest during the month of October. As of October 15th, there was short interest totaling 2,090,000 shares, an increase of 80.2% from the September 30th total of 1,160,000 shares. Based on an average daily volume of 430,800 shares, the short-interest ratio is currently 4.9 days. Approximately 2.2% of the shares of the company are short sold. Approximately 2.2% of the shares of the company are short sold. Based on an average daily volume of 430,800 shares, the short-interest ratio is currently 4.9 days.

Analyst Ratings Changes

PRQR has been the subject of several recent analyst reports. Zacks Research cut shares of ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Wednesday, October 15th. Evercore ISI reiterated an “outperform” rating on shares of ProQR Therapeutics in a research note on Friday, July 11th. Chardan Capital reiterated a “buy” rating and set a $4.00 price objective on shares of ProQR Therapeutics in a research note on Friday, August 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of ProQR Therapeutics in a research note on Wednesday, October 8th. Seven analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $7.14.

ProQR Therapeutics Price Performance

NASDAQ PRQR opened at $2.75 on Friday. ProQR Therapeutics has a 12 month low of $1.07 and a 12 month high of $4.21. The firm has a market capitalization of $289.33 million, a PE ratio of -5.98 and a beta of 0.23. The company’s 50 day simple moving average is $2.39 and its 200 day simple moving average is $2.07.

ProQR Therapeutics (NASDAQ:PRQR) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.06). The business had revenue of $4.33 million for the quarter, compared to the consensus estimate of $5.01 million. ProQR Therapeutics had a negative return on equity of 61.25% and a negative net margin of 238.52%. Sell-side analysts anticipate that ProQR Therapeutics will post -0.31 earnings per share for the current fiscal year.

Hedge Funds Weigh In On ProQR Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Osaic Holdings Inc. lifted its position in ProQR Therapeutics by 59.6% in the 2nd quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 4,500 shares in the last quarter. BNP Paribas Financial Markets lifted its position in ProQR Therapeutics by 28.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 121,494 shares of the biopharmaceutical company’s stock worth $248,000 after buying an additional 26,893 shares in the last quarter. Bank of America Corp DE lifted its position in ProQR Therapeutics by 25.7% in the 2nd quarter. Bank of America Corp DE now owns 119,198 shares of the biopharmaceutical company’s stock worth $243,000 after buying an additional 24,347 shares in the last quarter. Affinity Asset Advisors LLC lifted its position in ProQR Therapeutics by 6.5% in the 2nd quarter. Affinity Asset Advisors LLC now owns 3,499,512 shares of the biopharmaceutical company’s stock worth $7,139,000 after buying an additional 215,000 shares in the last quarter. Finally, Walleye Capital LLC lifted its position in ProQR Therapeutics by 5.6% in the 2nd quarter. Walleye Capital LLC now owns 531,977 shares of the biopharmaceutical company’s stock worth $1,085,000 after buying an additional 28,413 shares in the last quarter. Institutional investors and hedge funds own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).